Table 2 Comparison of pros and clinically meaningful events between semaglutide and control groups

Follow-up, years

2.9 ± 0.7

3.0 ± 0.7

BMI, kg/m²

 At last follow-up

23.1 ± 4.8

25.9 ± 4.5

 Change from baseline

-2.6 ± 3.1

0.9 ± 2.0

-3.4 (-2.9, -3.9)

FAAM sports subscale

 At last follow-up

84.7 ± 15.4

68.0 ± 19.5

 Change from baseline

21.6 ± 9.9

5.0 ± 12.6

16.3 (13.2, 19.3)

FAAM ADLsubscale

 At last follow-up

86.5 ± 12.3

75.5 ± 14.0

 Change from baseline

13.6 ± 7.0

4.2 ± 8.3

9.3 (7.2, 11.3)

FAOS pain subscale

 At last follow-up

89.9 ± 6.0

87.4 ± 5.5

 Change from baseline

6.0 ± 11.1

5.5 ± 10.8

2.3 (0.9, 3.6)

FAOS symptom subscale

 At last follow-up

81.6 ± 16.5

69.3 ± 20.9

 Change from baseline

12.3 ± 13.7

-1.1 ± 15.2

13.2 (9.5, 16.8)

FAOS ADL subscale

 At last follow-up

88.0 ± 10.9

83.1 ± 12.8

 Change from baseline

13.3 ± 15.8

10.5 ± 17.8

5.2 (2.1, 8.3)

FAOS sports subscale

 At last follow-up

80.6 ± 16.1

69.8 ± 15.1

 Change from baseline

17.8 ± 19.8

6.1 ± 20.2

10.2 (6.5, 13.9)

FAOS QoL subscale

 At last follow-up

73.8 ± 16.6

64.2 ± 17.4

 Change from baseline

19.5 ± 13.1

8.0 ± 12.9

11.2 (8.1, 14.2)

CAIT

 At last follow-up

23.9 ± 4.4

17.3 ± 4.8

 Change from baseline

8.4 ± 2.7

1.5 ± 2.0

6.9 (6.4, 7.4)

Number of ankle sprains during study period

0.3 ± 0.4

0.8 ± 0.8

-0.5 (-0.7, -0.3)

Number of ankle sprains during per year

0.1 ± 0.2

0.3 ± 0.3

-0.2 (-0.2, -0.1)

Incident ankle surgery

1 (1.4)

151 (7.8)